<DOC>
	<DOCNO>NCT02401230</DOCNO>
	<brief_summary>The purpose study determine whether use rectal lubricant affect well medication , Truvada , work prevent infection HIV someone expose HIV rectum .</brief_summary>
	<brief_title>PrEP , Lube , Rectal Mucosa MSM Risk HIV</brief_title>
	<detailed_description>Men sex men ( MSM ) continue disproportionately affected HIV . The majority HIV infection among MSM occur exposure rectal mucosa receptive anal intercourse ( RAI ) . During RAI , many MSM use lubricant , potentially cause mucosal inflammation damage . A new HIV prevention intervention , call pre-exposure prophylaxis ( PrEP ) , recommend MSM risk HIV infection take daily anti-HIV medication call Truvada ( tenofovir/emtricitabine ) highly effective . However , know use lubricant RAI interfere efficacy PrEP HIV prevention .</detailed_description>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>HIVnegative man report receptive anal sex another man last 6 month age 1849 year Male female transgender woman currently take hormonal therapy plan take hormonal therapy duration study Not currently take preexposure prophylaxis ( PrEP ) plan initiate study Able provide inform consent English No plan relocation next 6 month Willing undergo peripheral blood rectal biopsy sample Willing use study product direct Willing abstain receptive anal intercourse 3 day prior study visit 2 ( 416 week screen visit ) 10 day prior study visit 4 ( 526 week screen visit ) Willing abstain receptive anal intercourse 1 week study visit 2 ( 416 week screen visit ) study visit 4 ( 526 week screen visit ) History inflammatory bowel disease inflammatory , infiltrative , infectious vascular condition involve low gastrointestinal tract , judgment investigator , may worsen study procedure may significantly distort anatomy distal large bowel Significant laboratory abnormality baseline visit rectal biopsy , include limited : 1 . Hemoglobin ( Hbg ) â‰¤ 10 g/dL 2 . Partial thromboplastin time ( PTT ) &gt; 1.5x upper limit normal ( ULN ) international normalize ratio ( INR ) &gt; 1.5x ULN 3 . Platelet count &lt; 100,000 Any known medical condition , judgment investigator , increase risk local systemic complication endoscopic procedure pelvic examination , include limited : 1 . Uncontrolled severe cardiac arrhythmia 2 . Recent major abdominal , cardiothoracic , neurological surgery 3 . History uncontrolled bleeding diathesis 4 . History colonic , rectal , vaginal perforation , fistula , malignancy 5 . History evidence clinical examination ulcerative , suppurative , proliferative lesion anorectal vaginal mucosa , untreated sexually transmitted disease mucosal involvement Continued need , use 14 day prior enrollment , follow medication : 1 . Aspirin 4 dos nonsteroidal antiinflammatory drug ( NSAIDs ) 2 . Warfarin , heparin ( lowmolecular weight unfractionated ) , platelet aggregation inhibitor , fibrinolytic agent 3 . Any form rectally administer agent besides product lubricant douche use sexual intercourse Continued need , use 90 day prior enrollment , follow medication : 1 . Systemic immunomodulatory agent 2 . Supraphysiologic dos steroid 3 . Experimental medication , vaccine , biologicals Intent use HIV antiretroviral PrEP study , outside study procedure Symptoms untreated rectal sexually transmit infection ( e.g . rectal pain , discharge , bleeding , etc . ) Current use hormonal therapy Any clinical condition prior therapy , opinion investigator , would make patient unsuitable study unable comply study requirement</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Human Immunodeficiency Virus</keyword>
	<keyword>Acquired Immune Deficiency Syndrome Virus</keyword>
	<keyword>Pre-exposure Prophylaxis</keyword>
</DOC>